Bio-Techne Debt to Equity

The latest debt-to-equity ratio for TECH is 0.15. That is above the Healthcare sector average of -11.34. Investors often review this figure alongside Bio-Techne's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, TECH currently prints 0.15 for debt-to-equity ratio, while the sector average sits near -11.34. That is roughly 101.3% above the sector mean. Large gaps often invite a closer look at Bio-Techne's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.15 for Bio-Techne is not 'good' or 'bad' on its own. Compare it with the peer average (-11.34) and with TECH's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting TECH's debt-to-equity ratio (0.15), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bio-Techne's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.